Related Experiment Video
Updated: Jul 19, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy
Abstract:
Alemtuzumab has been proposed as a therapeutic agent in myeloma. CD52 was detected on plasma cells in 46/106 patients but levels were 30-fold lower than on alemtuzumab-responsive cells (n=138) and 8-fold lower than on alemtuzumab-resistant cells (n=57). The data suggest that myeloma plasma cells are unlikely to be depleted by alemtuzumab in most patients.
Insights
Alemtuzumab, a proposed multiple myeloma therapy, targets CD52. However, myeloma plasma cells express significantly lower CD52 levels, suggesting limited efficacy for this treatment in most patients.
Area of Science:
- Oncology
- Immunotherapy
- Hematology
Background:
- Alemtuzumab is investigated as a potential treatment for multiple myeloma.
- The therapeutic efficacy of alemtuzumab relies on its target, CD52.
Purpose of the Study:
- To evaluate the expression levels of CD52 on myeloma plasma cells.
- To determine the potential of alemtuzumab as a myeloma therapy based on CD52 expression.
Main Methods:
- CD52 expression was measured on plasma cells from multiple myeloma patients.
- Expression levels were compared between patient groups and known alemtuzumab-responsive/resistant cell lines.
Main Results:
- CD52 was detected on plasma cells in 46 out of 106 patients.
- Myeloma plasma cell CD52 levels were substantially lower (30-fold and 8-fold) than in alemtuzumab-responsive and resistant cells, respectively.
Conclusions:
- Myeloma plasma cells exhibit significantly reduced CD52 expression.
- Alemtuzumab is unlikely to effectively deplete myeloma plasma cells in the majority of patients due to low target expression.
